An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)

NCT00629564 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

GERD

Interventions

DRUG: Esomeprazole
DRUG: Esomeprazole

Sponsor

AstraZeneca